Literature DB >> 28419570

Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings.

V Sibaud1, C Eid2, V R Belum3, P Combemale4, B Barres5, L Lamant5, L Mourey6, C Gomez-Roca6, C L Estilo7, R Motzer8, E Vigarios9, M E Lacouture3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28419570      PMCID： PMC5645209          DOI： 10.1111/jdv.14284

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  10 in total

1.  Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.

Authors:  Shelley Ji Eun Hwang; Giuliana Carlos; Deepal Wakade; Karen Byth; Benjamin Y Kong; Shaun Chou; Matteo S Carlino; Richard Kefford; Pablo Fernandez-Penas
Journal:  J Am Acad Dermatol       Date:  2016-01-12       Impact factor: 11.527

2.  Histologic Assessment of Lichenoid Dermatitis Observed in Patients With Advanced Malignancies on Antiprogramed Cell Death-1 (anti-PD-1) Therapy With or Without Ipilimumab.

Authors:  Shaun Chou; Shelley Ji Eun Hwang; Giuliana Carlos; Deepal Wakade; Pablo Fernandez-Penas
Journal:  Am J Dermatopathol       Date:  2017-01       Impact factor: 1.533

3.  Anti-PD1-induced psoriasis: a study of 21 patients.

Authors:  J Bonigen; C Raynaud-Donzel; J Hureaux; N Kramkimel; A Blom; G Jeudy; A-L Breton; T Hubiche; C Bedane; D Legoupil; A Pham-Ledard; J Charles; M Pérol; E Gérard; P Combemale; D Bonnet; M-L Sigal; E Mahé
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-11-07       Impact factor: 6.166

4.  Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.

Authors:  Veronica J Shi; Nemanja Rodic; Scott Gettinger; Jonathan S Leventhal; Julia P Neckman; Michael Girardi; Marcus Bosenberg; Jennifer N Choi
Journal:  JAMA Dermatol       Date:  2016-10-01       Impact factor: 10.282

Review 5.  Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.

Authors:  Vincent Sibaud; Nicolas Meyer; Laurence Lamant; Emmanuelle Vigarios; Julien Mazieres; Jean Pierre Delord
Journal:  Curr Opin Oncol       Date:  2016-07       Impact factor: 3.645

6.  Increased B7-H1 expression on peripheral blood T cells in oral lichen planus correlated with disease severity.

Authors:  Gang Zhou; Jing Zhang; Xiang-wei Ren; Jing-yu Hu; Ge-fei Du; Xue-yi Xu
Journal:  J Clin Immunol       Date:  2012-03-21       Impact factor: 8.317

7.  Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.

Authors:  Lars Hofmann; Andrea Forschner; Carmen Loquai; Simone M Goldinger; Lisa Zimmer; Selma Ugurel; Maria I Schmidgen; Ralf Gutzmer; Jochen S Utikal; Daniela Göppner; Jessica C Hassel; Friedegund Meier; Julia K Tietze; Ioannis Thomas; Carsten Weishaupt; Martin Leverkus; Renate Wahl; Ursula Dietrich; Claus Garbe; Michael C Kirchberger; Thomas Eigentler; Carola Berking; Anja Gesierich; Angela M Krackhardt; Dirk Schadendorf; Gerold Schuler; Reinhard Dummer; Lucie M Heinzerling
Journal:  Eur J Cancer       Date:  2016-04-13       Impact factor: 9.162

Review 8.  Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.

Authors:  Emmanuelle Vigarios; Joel B Epstein; Vincent Sibaud
Journal:  Support Care Cancer       Date:  2017-02-22       Impact factor: 3.603

9.  Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy.

Authors:  Kurt B Schaberg; Roberto A Novoa; Heather A Wakelee; Jinah Kim; Christine Cheung; Sandhya Srinivas; Bernice Y Kwong
Journal:  J Cutan Pathol       Date:  2016-02-10       Impact factor: 1.587

Review 10.  Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.

Authors:  V R Belum; B Benhuri; M A Postow; M D Hellmann; A M Lesokhin; N H Segal; R J Motzer; S Wu; K J Busam; J D Wolchok; M E Lacouture
Journal:  Eur J Cancer       Date:  2016-04-01       Impact factor: 9.162
  10 in total
  14 in total

Review 1.  [Immunopathology of cutaneous drug eruptions].

Authors:  D Niebel; J Wenzel
Journal:  Pathologe       Date:  2018-11       Impact factor: 1.011

2.  Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study.

Authors:  D M Barrios; G S Phillips; A Freites-Martinez; M Hsu; K Ciccolini; A Skripnik Lucas; M A Marchetti; A M Rossi; E H Lee; L Deng; A Markova; P L Myskowski; M E Lacouture
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-02-05       Impact factor: 6.166

Review 3.  Immune-related cutaneous adverse events due to checkpoint inhibitors.

Authors:  Evelyn Wang; Lukas Kraehenbuehl; Kwami Ketosugbo; Jeffrey A Kern; Mario E Lacouture; Donald Y M Leung
Journal:  Ann Allergy Asthma Immunol       Date:  2021-02-17       Impact factor: 6.248

Review 4.  Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.

Authors:  Chieh-Hsun Chen; Hsin-Su Yu; Sebastian Yu
Journal:  Curr Oncol       Date:  2022-04-18       Impact factor: 3.109

Review 5.  Mogamulizumab-induced Mucocutaneous Lichenoid Reaction: A Case Report and Short Review.

Authors:  Megan H Trager; Donatienne de Clippelé; Caroline Ram-Wolff; Adèle de Masson; Marie-Dominique Vignon-Pennamen; Maxime Battistella; Laurence Michel; Martine Bagot; Gabor Dobos
Journal:  Acta Derm Venereol       Date:  2020-05-28       Impact factor: 3.875

Review 6.  Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management.

Authors:  Zoe Apalla; Bernardo Rapoport; Vincent Sibaud
Journal:  Int J Womens Dermatol       Date:  2021-10-23

7.  Nivolumab-induced lichenoid granulomatous stomatitis in a patient with advanced melanoma: A case report.

Authors:  P Gouveris; E A Georgakopoulou; A Grigoraki; D N Zouki; V E Kardara; S Ioannou; D Tryfonopoulos; S Demiri; I Gkouveris
Journal:  Mol Clin Oncol       Date:  2022-02-08

Review 8.  Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases.

Authors:  Yoshiaki Yura; Masakazu Hamada
Journal:  Cancers (Basel)       Date:  2022-02-04       Impact factor: 6.639

Review 9.  Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.

Authors:  Mario Lacouture; Vincent Sibaud
Journal:  Am J Clin Dermatol       Date:  2018-11       Impact factor: 7.403

10.  Chronic and Severe Non-Lichenoid Oral Ulcers Induced by Nivolumab - Diagnostic and Therapeutic Challenge: A Case Report.

Authors:  Andrés F Cardona; Alejandro Ruiz-Patiño; Luisa Ricaurte; Zyanya Lucia Zatarain-Barrón; Feliciano Barrón; Oscar Arrieta
Journal:  Case Rep Oncol       Date:  2020-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.